

# Direct Analysis of Opioids and Metabolites in Oral Fluid by Mixed-mode $\mu$ Elution SPE Combined with UPLC-MS/MS for Forensic Toxicology

Jonathan P. Danaceau, Erin E. Chambers, Kenneth J. Fountain

Waters Corporation



*For forensic toxicology use only.*

---

## Abstract

This application highlights a method for the analysis of 26 opioid drugs and metabolites by mixed-mode SPE followed by UPLC-MS/MS. Glucuronide metabolites are directly analyzed, eliminating the need for enzymatic or chemical hydrolysis.

### Benefits

- Analysis of all metabolites without enzymatic hydrolysis
- Comprehensive panel of 26 opiate and opioid analgesic compounds
- Rapid and simple sample preparation in oral fluid
- Linear, accurate and precise responses for all analytes and metabolites

---

## Introduction

The analysis of natural and synthetic opioid drugs continues to be an important aspect of forensic toxicology. In the past, analyses were typically conducted by GC-MS after first subjecting the samples to acid or enzymatic hydrolysis to liberate glucuronide metabolites.<sup>1</sup> With the advent of LC-MS/MS techniques, glucuronide metabolites can now be analyzed directly.<sup>2-5</sup> Direct analyses of these metabolites can eliminate the risk of false negatives due to incomplete hydrolysis, as enzymatic efficiency can vary greatly depending upon the enzyme used and the drug substrate analyzed.<sup>6</sup>

One particular sample matrix that has become increasingly popular recently is oral fluid. Unlike urine, oral fluid can be more indicative of current impairment or intoxication. Collection can also be easily accomplished without the privacy issues and adulteration possibilities associated with urine collection. Oral fluid also has similar advantages over blood as a matrix. Once again, collection is much easier, since it is non-invasive and there is no need for specialized training. This application highlights a method for the analysis of 26 opioid drugs and metabolites by mixed-mode SPE followed by UPLC-MS/MS. Glucuronide metabolites are directly analyzed, eliminating the need for enzymatic or chemical hydrolysis.

---

## Experimental

### Final method conditions

#### LC conditions

LC system:	ACQUITY UPLC I-Class
Column:	ACQUITY UPLC BEH C <sub>18</sub> 1.7 µm; 2.1 x 100 mm (p/n 186002352)
Column temp.:	30 °C
Injection volume:	10 µL
Flow rate:	0.4 mL/min.
Mobile phase A:	0.1% formic acid in MilliQ water
Mobile phase B:	0.1% formic acid in ACN
Weak needle wash:	2% ACN in water
Strong needle wash:	10% ACN in water
Gradient:	Initial Conditions were 2% B. The %B was increased to 52.8% over 6 minutes and then returned to 2% over 0.5 min. The system was allowed to re-equilibrate for 1.5 min. The total cycle time was 8.0 min.

### MS conditions

MS System:	XEVO TQD Mass Spectrometer
------------	----------------------------

Ionization mode:	ESI Positive
Acquisition mode:	MRM (See Table 1 for transitions)
Capillary voltage:	1 kV
Collision energy (eV):	Optimized for individual compounds (See Table 1)
Cone voltage (V):	Optimized for individual compounds (See Table 1)
Data management:	All data was acquired and analyzed using Waters MassLynx Software v.4.1

## Materials

All compounds and internal standards (IS) were purchased from Cerilliant (Round Rock, TX). Complementary, deuterated internal standards were used for all compounds with the exception of hydromorphone-3-glucuronide, codeine-6-glucuronide, norbuprenorphine-glucuronide, norfentanyl, and buprenorphine-glucuronide. For these compounds, a deuterated IS with the most similar response was chosen as a surrogate.

A combined stock solution of all compounds (10 µg/mL; 2.5 µg/mL for fentanyl and norfentanyl) was prepared in methanol. Working solutions were prepared daily by preparing high standards and QCs in matrix (oral fluid) and performing serial dilutions to achieve the desired concentrations. Calibrator concentrations ranged from 5-500 ng/mL for all analytes with the exception of fentanyl and norfentanyl, which were prepared at 25% of the concentration of the other analytes (1.25-125 ng/mL). A combined internal standard stock solution (5 µg/mL; 1.25 µg/mL for fentanyl and norfentanyl) was prepared in methanol. Working IS solutions were prepared daily in MeOH at 500 ng/mL.

## Sample preparation

### Sample collection

Oral fluid samples were collected with the Quantisal collection device from Immunalysis according to the manufacturer's directions. The collection applicator was saturated with oral fluid, and then placed in the

collection vial, which contained 3.0 mL of sample stabilization buffer. This was claimed to be the equivalent of collecting 1.0 mL  $\pm$  0.1 mL of sample. The collection kit was stored overnight to simulate the transit time of the sample and to allow for complete equilibration between the sample in the applicator and the stabilization buffer in the collection vial.

## Solid-Phase Extraction

400  $\mu$ L aliquots of buffer stabilized oral fluid samples (equivalent to 100  $\mu$ L oral fluid) were pretreated by adding 200  $\mu$ L 4% H<sub>3</sub>PO<sub>4</sub> and 20  $\mu$ L of the working IS mixture (500 ng/mL in MeOH). Wells in the 96-well Oasis MCX  $\mu$ Elution plate (p/n 186001830BA) were conditioned with 200  $\mu$ L MeOH followed by 200  $\mu$ L MilliQ water. The entire pretreated sample was then added to each well. After loading, the wells were washed with 200  $\mu$ L of 2% formic acid, followed by 200  $\mu$ L of methanol and 200  $\mu$ L of isopropanol (IPA). All samples were then eluted with 2 x 50  $\mu$ L of 60:40 ACN:IPA containing 5% of a concentrated NH<sub>4</sub>OH solution (Fisher, 20-22%). After elution, all samples were evaporated under N<sub>2</sub> to dryness at 37 °C (approximately 5 min.) and reconstituted with a solution of 98:2 water: ACN containing 0.1% formic acid and 0.1% (by volume) human plasma. 10  $\mu$ L was injected onto the LC-MS/MS system.

## Recovery calculation

Recovery was calculated according to the following equation:

$$\% \text{ Recovery} = \left( \frac{\text{Area A}}{\text{Area B}} \right) \times 100\%$$

Area A refers to the peak area of a sample spiked with analytes before extraction, and area B refers to the peak area of a sample in which the analytes were spiked into the final eluate after extraction.

---

## Results and Discussion

The 26 compounds and metabolites screened are listed in Table 1 and constitute a comprehensive panel of natural opiate drugs, semi-synthetic opioids, and synthetic narcotic analgesic compounds. Most of the compounds are weak bases, with pK<sub>a</sub> values of approximately 8-9. They have a wide range of polarities, with LogP values ranging from -3.48 for morphine-3 $\beta$ -d-glucuronide to 5.0 for methadone. MRM transitions, cone

voltage and collision energies are also listed in Table 1.

## Chromatography

A representative chromatogram of all compounds is shown in Figure 1. Peak assignments can be found in Table 1. Using an ACQUITY UPLC BEH C<sub>18</sub> Column (1.7 µm, 2.1 x 100 mm), we were able to analyze all compounds in under 5.5 minutes with baseline separation between all critical pairs of isomers, such as morphine-3-glucuronide, morphine-6-glucuronide and hydromorphone-3-glucuronide (compounds 1, 3, and 4, respectively).

	Compound	RT	Formula	Molecular Mass	MRM Transitions	Cone Voltage	Coll. Energy
1	Morphine-3β-D-glucuronide	1.13	C <sub>23</sub> H <sub>27</sub> NO <sub>9</sub>	461.17	462.2 > 286.1, 201.1	58	30, 52
2	Oxymorphone-3β-D-glucuronide	1.12	C <sub>23</sub> H <sub>27</sub> NO <sub>10</sub>	477.16	478.2 > 284.1, 227.1	56	44, 68
3	Hydromorphone-3β-D-glucuronide	1.24	C <sub>23</sub> H <sub>27</sub> NO <sub>9</sub>	461.17	462.2 > 286.1, 185.1	58	50, 70
4	Morphine-6β-D-glucuronide	1.37	C <sub>23</sub> H <sub>27</sub> NO <sub>9</sub>	461.17	462.2 > 286.2, 113.0	66	50, 65
5	Morphine	1.40	C <sub>17</sub> H <sub>19</sub> NO <sub>3</sub>	285.14	286.1 > 201.1, 165.1	54	28, 34
6	Oxymorphone	1.51	C <sub>17</sub> H <sub>19</sub> NO <sub>4</sub>	301.13	302.2 > 284.2, 227.1	44	30, 37
7	Hydromorphone	1.65	C <sub>17</sub> H <sub>19</sub> NO <sub>3</sub>	285.13	286.1 > 185.0, 157.0	65	46, 62
8	Codeine-6β-D-glucuronide	1.90	C <sub>24</sub> H <sub>29</sub> NO <sub>9</sub>	475.18	476.2 > 300.2, 113.0	70	50, 60
9	Dihydrocodeine	1.97	C <sub>18</sub> H <sub>23</sub> NO <sub>3</sub>	301.17	302.2 > 199.1, 128.1	60	45, 75
10	Codeine	2.04	C <sub>18</sub> H <sub>21</sub> NO <sub>3</sub>	299.15	300.2 > 199.1, 165.1	58	42, 54
11	Oxycodone	2.26	C <sub>18</sub> H <sub>21</sub> NO <sub>4</sub>	315.15	316.2 > 298.2, 241.1	44	25, 44
12	6-Acetylmorphine (6-AM)	2.30	C <sub>19</sub> H <sub>21</sub> NO <sub>4</sub>	327.15	328.2 > 165.1, 211.1	60	58, 40
13	O-desmethyl Tramadol	2.35	C <sub>15</sub> H <sub>23</sub> NO <sub>2</sub>	249.17	250.2 > 58.0	30	20
14	Hydrocodone	2.38	C <sub>18</sub> H <sub>21</sub> NO <sub>3</sub>	299.15	300.2 > 199.1, 171.0	65	40, 58
15	Norbuprenorphine-glucuronide	2.74	C <sub>31</sub> H <sub>43</sub> NO <sub>10</sub>	589.29	590.3 > 414.3, 101.0	74	62, 80
16	Norfentanyl	2.82	C <sub>14</sub> H <sub>20</sub> N <sub>2</sub> O	232.16	233.2 > 177.2, 150.1	38	18, 24
17	Tramadol	3.10	C <sub>16</sub> H <sub>25</sub> NO <sub>2</sub>	263.19	264.2 > 58.0	30	25
18	Normeperidine	3.45	C <sub>14</sub> H <sub>19</sub> NO <sub>2</sub>	233.1	234.1 > 160.1, 131.1	40	20, 35
19	Meperidine	3.46	C <sub>15</sub> H <sub>21</sub> NO <sub>2</sub>	247.16	248.2 > 220.2, 147.1	50	34, 28
20	Buprenorphine-glucuronide	3.52	C <sub>35</sub> H <sub>49</sub> NO <sub>10</sub>	643.34	644.3 > 468.3, 396.4	75	60, 80
21	Norbuprenorphine	3.64	C <sub>25</sub> H <sub>35</sub> NO <sub>4</sub>	413.26	414.3 > 101.0, 187.2	70	55, 55
22	Fentanyl	4.15	C <sub>22</sub> H <sub>28</sub> N <sub>2</sub> O	336.22	337.2 > 188.2, 105.1	50	36, 56
23	Buprenorphine	4.41	C <sub>29</sub> H <sub>41</sub> NO <sub>4</sub>	467.3	468.3 > 396.3, 101.0	82	55, 68
24	EDDP+	4.63	C <sub>20</sub> H <sub>24</sub> N <sup>+</sup>	278.19	278.2 > 249.2, 234.2	60	33, 40
25	Propoxyphene	5.02	C <sub>22</sub> H <sub>29</sub> NO <sub>2</sub>	339.3	340.3 > 266.2, 128.0	20	14, 60
26	Methadone	5.09	C <sub>21</sub> H <sub>27</sub> NO	309.2	310.3 > 265.2, 105.0	32	20, 38

Table 1. Chemical names, formulae, retention times, and MS conditions of test compounds.




Figure 1. Chromatography of opiates and synthetic analgesic compounds. Peak assignments are listed in Table 1.

### Analyte recovery

Recovery was evaluated using both IPA and MeOH as a co-elution solvent with ACN. Both solvents resulted in similar recovery patterns for the 26 opiate compounds. When MeOH was used, recoveries were slightly better for the 4 earliest eluting glucuronide metabolites. However, the average recovery for all compounds was improved when using IPA. Eluting with 60:40 ACN:IPA resulted in an average recovery of 78.8% for all compounds vs. 74.2% using 60:40 ACN:MeOH. Figure 2 shows the average recovery for all compounds when eluted with 60:40 ACN:IPA.






Figure 2. Recovery of opioid compounds from oral fluid extracted using Oasis MCX  $\mu$ Elution Plates. Error bars indicate standard deviations (N=4).

For this application, evaporation of the organic eluate and reconstitution in a high aqueous solution (2% ACN) was necessary to prevent strong solvent effects that would otherwise affect the chromatography of the glucuronide metabolites by causing peak distortion that prevents proper retention and integration of the resulting peaks. However, use of the Oasis MCX Plate in the  $\mu$ Elution Plate format results in only 100  $\mu$ L of eluate that is easily evaporated in under 5 minutes. An additional benefit of using the  $\mu$ Elution plate format is that only 100  $\mu$ L of sample is needed for the assay. This can be a significant advantage for oral fluid analysis, since sample sizes are often quite small (1.0 mL). The ability to use minimal sample volumes allows for repeat analysis, or the use of additional aliquots for other analyses, if necessary.

### Linearity, accuracy, and precision

Calibration and quality control (QC) results indicate that this method is linear, accurate and precise. Calibration standards were prepared in oral fluid at concentrations ranging from 5-500 ng/mL (1.25-125 ng/mL for fentanyl and norfentanyl). An example calibration curve is shown for hydrocodone in Figure 3. The mean accuracies and  $R^2$  values for the calibration curves are listed in Table 2. All compounds had  $R^2$  values of at least 0.989 and many were 0.995 or greater. Quality control samples (N=4) were prepared at 4 concentrations: 7.5, 25, 150, and 300 ng/mL. Analytical accuracy and precision were very good. With only 2 exceptions, all QC results were within 15% of their intended values and all but 2 points had % CVs that were



under 15%.

Compound name: Hydrocodone

Correlation coefficient:  $r = 0.999256$ ,  $r^2 = 0.998513$

Calibration curve:  $0.656868 * x + 0.0333136$

Response type: Internal Std (Ref 26), Area \* (IS Conc. / IS Area)

Curve type: Linear, Origin: Exclude, Weighting:  $1/x^2$ , Axis trans: None




Figure 3. Calibration curve for hydrocodone.  $R^2 = 0.998$ . Fit – linear  $1/x^2$  weighting.

Compound	R <sup>2</sup>	QC Concentration (ng/mL)							
		7.5		25		150		300	
		%CV	Bias	%CV	Bias	%CV	Bias	%CV	Bias
Morphine-3-β-d-glucuronide	0.995	10.2%	14.4%	3.5%	9.0%	6.8%	5.3%	3.3%	2.0%
Oxymorphone-3-b-d-glucuronide	0.994	14.4%	14.9%	5.9%	-0.8%	3.8%	11.2%	1.9%	4.2%
Hydromorphone-3-b-d-glucuronide	0.992	8.2%	8.0%	5.4%	2.2%	7.2%	4.9%	3.9%	2.5%
Morphine-6-gluc	0.993	17.4%	0.8%	6.4%	2.4%	4.6%	3.6%	3.9%	3.3%
Morphine	0.989	15.3%	19.7%	2.7%	18.2%	12.2%	11.6%	6.9%	5.9%
Oxymorphone	0.997	9.2%	2.7%	6.4%	3.3%	2.6%	4.1%	2.7%	5.1%
Hydromorphone	0.997	7.7%	1.1%	3.6%	5.1%	3.2%	5.4%	3.8%	6.4%
Codeine-6-β-d-glucuronide	0.993	2.6%	-7.3%	5.2%	1.9%	3.9%	-3.8%	6.0%	5.7%
Dihydrocodeine	0.996	2.3%	6.7%	3.6%	11.4%	2.7%	4.4%	2.2%	1.5%
Codeine	0.994	8.7%	7.2%	3.7%	11.7%	3.8%	4.3%	3.9%	1.4%
Oxycodone	0.996	7.0%	5.3%	5.6%	10.6%	5.1%	7.5%	2.7%	2.2%
6-Acetylmorphine (6-AM)	0.996	5.3%	5.4%	3.6%	8.5%	3.6%	3.3%	7.1%	4.5%
O-desmethyl Tramadol	0.999	5.6%	6.1%	2.5%	7.7%	2.1%	5.8%	1.7%	5.4%
Hydrocodone	0.998	5.6%	6.4%	3.4%	4.6%	2.7%	4.7%	3.0%	6.6%
Norbuprenorphine-glucuronide	0.992	2.5%	-11.4%	2.8%	1.7%	7.1%	-4.9%	5.9%	8.8%
Norfentanyl	0.998	7.0%	0.8%	3.9%	8.3%	2.9%	2.6%	3.3%	4.9%
Tramadol	0.999	4.8%	6.4%	3.1%	8.8%	2.6%	6.7%	2.2%	4.8%
Normeperidine	0.999	4.8%	-0.7%	3.3%	3.5%	2.2%	3.1%	2.8%	2.4%
Meperidine	0.999	5.5%	5.2%	4.1%	4.9%	2.6%	6.6%	2.5%	6.2%
Buprenorphine-gluc	0.999	4.8%	-4.5%	7.0%	2.2%	3.9%	1.1%	3.7%	7.1%
Norbuprenorphine	0.996	5.9%	5.4%	3.6%	8.3%	2.3%	4.8%	1.5%	2.9%
Fentanyl	0.999	4.6%	4.8%	2.5%	7.4%	2.7%	6.8%	1.5%	6.4%
Buprenorphine	0.999	4.5%	6.5%	2.8%	8.1%	3.0%	7.9%	1.5%	7.5%
EDDP+	0.999	4.7%	4.8%	2.4%	5.8%	2.7%	6.8%	2.5%	7.3%
Propoxyphene	0.999	3.8%	6.8%	3.0%	8.6%	2.4%	7.0%	2.2%	7.0%
Methadone	0.999	5.3%	6.1%	3.2%	8.0%	3.0%	6.8%	2.4%	6.5%

Table 2. Regression coefficients ( $R^2$ ) and quality control statistics for opioid compounds extracted from oral fluid using Oasis MCX  $\mu$ Elution Plates. For each concentration, mean, %CV and % bias are listed (N=4).

## Conclusion

The method presented here demonstrates the advantages of mixed-mode  $\mu$ Elution SPE combined with UPLC-MS/MS for the analysis of 26 opioid compounds and metabolites of interest. All compounds are analyzed in under 5.5 minutes with complete resolution of all isobaric compound pairs. Linearity, analytical accuracy, and precision were excellent over the entire calibration range for all 26 compounds. The  $\mu$ Elution

format enabled the extraction of 100 µL aliquots of oral fluid, leaving the remaining sample for additional assays, or repeat analyses, if necessary. The ability to achieve LOQs of 5 ng/mL for nearly all analytes and the ability to measure glucuronide metabolites directly without hydrolysis make this method well suited for the analysis of these compounds in oral fluid.

---

## References

1. Goldberger B.A., and Cone E.J., Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry. *Journal of Chromatography A*, 1994. 674(1-2): p. 73-86.
  2. Gustavsson E., et al., Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing. *Journal of Mass Spectrometry*, 2007. 42(7): p. 881-889.
  3. Murphy C.M. and Huestis M.A., LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-β-D-glucuronide, morphine-6-β-D-glucuronide, and codeine-6-β-D-glucuronide in human urine. *Journal of Mass Spectrometry*, 2005. 40(11): p. 1412-1416.
  4. Edinboro L.E., Backer R.C., and Poklis A., Direct Analysis of Opiates in Urine by Liquid Chromatography-Tandem Mass Spectrometry. *Journal of Analytical Toxicology*, 2005. 29(7): p. 704-710.
  5. French D., Wu A., and Lynch K., Hydrophilic interaction LC-MS/MS analysis of opioids in urine: significance of glucuronide metabolites. *Bioanalysis*, 2011. 3(23): p. 2603-2612.
  6. Wang, P., et al., Incomplete Recovery of Prescription Opioids in Urine using Enzymatic Hydrolysis of Glucuronide Metabolites. *Journal of Analytical Toxicology*, 2006. 30(8): p. 570-575.
- 

## Featured Products

MassLynx MS Software <<https://www.waters.com/513662>>

Xevo TQD Triple Quadrupole Mass Spectrometry <<https://www.waters.com/134608730>>

ACQUITY UPLC I-Class PLUS System <<https://www.waters.com/134613317>>

720004838, June 2014

©2019 Waters Corporation. All Rights Reserved.